Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 381

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only

Open access
Hugosson, Jonas, Månsson, Marianne, Wallström, Jonas, Axcrona, Ulrika, Carlsson, Sigrid V., Egevad, Lars, Geterud, Kjell, Khatami, Ali, Kohestani, Kimia, Pihl, Carl-Gustaf, Socratous, Andreas, Stranne, Johan, Godtman, Rebecka Arnsrud, Hellström, Mikael·2022·New England Journal of Medicine

Abstract

BACKGROUND: Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. METHODS: We invited 37,887 men who were 50 to 60 years of age to undergo regular prostate-specific antigen (PSA) screening. Participants with a PSA level of 3 ng per milliliter or higher underwent magnetic resonance imaging (MRI) of the prostate; one third of the participants were randomly assigned to a reference group that underwent systematic biopsy as well as targeted biopsy of suspicious lesions shown on MRI. The remaining participants were assigned to the experimental group and underwent MRI-targeted biopsy only. The primary outcome was clinically insignificant prostate cancer, defined as a Gleason score of 3+3. The secondary outcome was clinically significant prostate cancer, defined as a Gleason score of at least 3+4. Safety was also assessed. RESULTS: Of the men who were invited to undergo screening, 17,980 (47%) participated in the trial. A total of 66 of the 11,986 participants in the experimental group (0.6%) received a diagnosis of clinically insignificant prostate cancer, as compared with 72 of 5994 participants (1.2%) in the reference group, a difference of -0.7 percentage points (95% confidence interval [CI], -1.0 to -0.4; relative risk, 0.46; 95% CI, 0.33 to 0.64; P<0.001). The relative risk of clinically significant prostate cancer in the experimental group as compared with the reference group was 0.81 (95% CI, 0.60 to 1.1). Clinically significant cancer that was detected only by systematic biopsy was diagnosed in 10 participants in the reference group; all cases were of intermediate risk and involved mainly low-volume disease that was managed with active surveillance. Serious adverse events were rare (<0.1%) in the two groups. CONCLUSIONS: The avoidance of systematic biopsy in favor of MRI-directed targeted biopsy for screening and early detection in persons with elevated PSA levels reduced the risk of overdiagnosis by half at the cost of delaying detection of intermediate-risk tumors in a small proportion of patients. (Funded by Karin and Christer Johansson's Foundation and others; GÖTEBORG-2 ISRCTN Registry number, ISRCTN94604465.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2209454

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 381

Metadata

Authors
Hugosson, J., Månsson, M., Wallström, J., Axcrona, U., Carlsson, S. V., Egevad, L., Geterud, K., Khatami, A., Kohestani, K., Pihl, C.-G., Socratous, A., Stranne, J., Godtman, R. A., & Hellström, M.
Venue
New England Journal of Medicine
Published
2022-12-08
Volume
387
Issue
23
Pages
2126-2137
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4311843617
Cited by
381
References
23
FWCI
41.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. https://app.cochat.ai/papers/10.1056/nejmoa2209454
The paper
Hugosson, J., Månsson, M., Wallström, J., Axcrona, U., Carlsson, S. V., Egevad, L., Geterud, K., Khatami, A., Kohestani, K., Pihl, C.-G., Socratous, A., Stranne, J., Godtman, R. A., & Hellström, M. (2022). Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2209454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.